Medable launched an Agentic AI designed to assist principal investigators in reviewing and reconciling electronic clinical outcome assessment data, shifting routine reconciliation tasks toward context‑aware automation while preserving human sign‑off. Separately, Galux raised a $29 million Series B to scale AI‑designed biologics and protein therapeutics. Together these developments show investment in operational AI for trials and AI‑driven design for biologics — two adjacent fronts where algorithmic tools aim to reduce timelines and investigator burden. Medable emphasized human‑in‑the‑loop controls and regulatory readiness; Galux will apply funding to advance AI optimization and scale manufacturing partnerships.